{"entity":{"id":"nct06127238","kind":"trial","name":"Study of ST-1898 in Advanced Renal Cell Carcinoma","aka":[],"tldr":"A phase 1/2 trial of ST-1898 tablets in renal cell carcinoma, run by Beijing Scitech-Mq Pharmaceuticals Limited, active and no longer recruiting.","summary":"Study of ST-1898 in Advanced Renal Cell Carcinoma is a phase 1/2 interventional study registered as NCT06127238 by Beijing Scitech-Mq Pharmaceuticals Limited, with 90 participants enrolled, started 2023-02-07 and due to reach its primary completion in 2025-12. Interventions recorded: ST-1898 tablets.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06127238","url":"https://clinicaltrials.gov/study/NCT06127238"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06127238","phase":"1/2","setting":"A Phase Ib/II Study of ST-1898 to Evaluate the Efficacy and Safety in Patients With Renal Cell Carcinoma (RCC)","sponsor":"Beijing Scitech-Mq Pharmaceuticals Limited","enrolled":90,"outcomes":[]},"route":"/trials/nct06127238/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"company":[{"id":"beijing-scitech-mq-pharmaceuticals","kind":"company","name":"Beijing Scitech-Mq Pharmaceuticals","route":"/companies/beijing-scitech-mq-pharmaceuticals/"}]}}